Based on the above properties of Apo-C1, we can hypothesize that it may have distinct functions depending on its distribution among lipoproteins (with a proatherogenic effect in combination with VLDL-C and an antiatherosclerotic effect in combination with HDL-C particles), therefore a clear influence of Apo-C1 on cardiometabolic risk is difficult to establish and further research needs to be done, especially in patients with AF. Here, APOC1 is linked to atrial fibrillation.